Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Short term Debt (2016)

Gyre Therapeutics (GYRE) has disclosed Short term Debt for 7 consecutive years, with $28000.0 as the latest value for Q3 2016.

  • On a quarterly basis, Short term Debt fell 95.86% to $28000.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $28000.0, a 95.86% decrease, with the full-year FY2015 number at $1.2 million, changed N/A from a year prior.
  • Short term Debt was $28000.0 for Q3 2016 at Gyre Therapeutics, down from $130000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.2 million in Q4 2015 to a low of $28000.0 in Q3 2016.
  • A 5-year average of $690625.0 and a median of $847500.0 in 2012 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 41.42% in 2015, then crashed 95.86% in 2016.
  • Gyre Therapeutics' Short term Debt stood at $851000.0 in 2012, then grew by 0.24% to $853000.0 in 2013, then tumbled by 43.96% to $478000.0 in 2014, then skyrocketed by 141.84% to $1.2 million in 2015, then plummeted by 97.58% to $28000.0 in 2016.
  • Per Business Quant, the three most recent readings for GYRE's Short term Debt are $28000.0 (Q3 2016), $130000.0 (Q2 2016), and $196000.0 (Q1 2016).